PALI - Multiplikator Forward P/S Palisade Bio

Patents for LB1148 and stringent FDA oversight create significant barriers to entry for competitors. The application of automated enzyme synthesis increases drug purity, as evidenced by the forward P/S trend; here 397.10 reflects the latest metric level. The implementation of software robots for clinical trial data analysis will provide Palisade Bio, Inc. (PALI) with a further technological leap in the treatment of gastrointestinal inflammation.

PALI palisadebio.com: Rasio kapitalisasi marang dodolan sing dikarepake ing interval 21.05.2023 - 13.11.2026

palisadebio.com - rincian analitis lan metrik utama (PALI)

- rega pasar lan target rega analis:

Bagan rega Palisade Bio, Inc.|PALI - Bagan rega target

- statistik kapitalisasi pasar:

Kapitalisasi pasar Palisade Bio, Inc.|PALI - Rega Tumbas Perusahaan

- statistik nilai buku emiten:

Aset Bersih saben Siji Saham Palisade Bio|PALI - Pambiji Buku Bisnis|Rasio Kapitalisasi Pasar marang Nilai Buku palisadebio.com|PALI - Total Aset Perusahaan

- data liabilitas lan likuiditas perusahaan:

- data bathi bisnis lan rasio investasi:

PALI - Asil keuangan resik|Bathi sing dikarepake Palisade Bio, Inc.|PALI - Kapitalisasi marang bathi|Prakiraan rega marang bathi Palisade Bio, Inc.|PALI - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Palisade Bio, Inc.|PALI - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Palisade Bio|PALI - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan palisadebio.com|PALI - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep Palisade Bio, Inc.

- indikator volume dodolan lan pendapatan:

PALI - Pendapatan reged perusahaan|Prakiraan pendapatan perusahaan Palisade Bio|PALI - Rasio rega marang dodolan|Multiplikator Forward P/S Palisade Bio, Inc.

Analisis wiwitan perusahaan:Palisade Bio, Inc. (PALI)

The forward P/S ratio reflects the proportion between current market capitalization and projected sales volume, allowing investors to identify the risk of overpaying amid inflated market expectations. Analyzing the forward price-to-sales ratio helps evaluate the value management efficiency of Palisade Bio, Inc. (PALI), whose narrow specialization in AI-driven molecule selection for gastrointestinal treatment minimizes generic pressure and justifies a premium asset valuation.

Pesaing wigati

Rasio rega marang prakiraan pendapatan Phathom Pharmaceuticals, Inc. PHAT|Terns Pharma - Rasio rega marang prakiraan pendapatan|Ironwood Pharmaceuticals Inc - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Curanex Pharmaceuticals Inc CURX|immuron.com.au (IMRN) - Rasio rega marang prakiraan pendapatan|EVOK - Rasio kapitalisasi marang dodolan sing dikarepake|ENTO (Entero Therapeutics Inc.) - Multiplikator Forward P/S|Multiplikator Forward P/S RedHill|Multiplikator Forward P/S JAGX|Biora Therapeutics, Inc - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S MORF (Morphic Holding, Inc.)